Keytruda

Merck and Eisai tease results for renal carcinoma treatment
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Flag link:
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
Fierce Pharma
ASCO 2023
Merck
Keytruda
cervical cancer
Flag link:
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Flag link:
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Biopharma Reporter
Merck
Moderna Therapeutics
cancer
cancer vaccines
Keytruda
clinical trials
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
BioSpace
Merck
Seagen
Astellas
Keytruda
Padcev
metastatic urothelial carcinoma
FDA
Flag link:
FDA grants full approval to Keytruda in tumor-agnostic setting
FDA grants full approval to Keytruda in tumor-agnostic setting
Endpoints
Merck
Keytruda
tumor agnostic
solid tumors
Flag link:
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
Fierce Pharma
GSK
Merck
Keytruda
Jemperli
cancer
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Flag link:
Keytruda Unlocked: How Should Merck Proceed with Trials?
Keytruda Unlocked: How Should Merck Proceed with Trials?
BioSpace
Keytruda
Merck
cancer
clinical trials
Flag link:
Merck reports positive data from malignant pleural mesothelioma trial
Merck reports positive data from malignant pleural mesothelioma trial
Clinical Trials Arena
Merck
Canadian Cancer Trials Group
clinical trials
Keytruda
mesothelioma
Flag link:
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Flag link:
Merck reports two Phase 3 study misses for Keytruda
Merck reports two Phase 3 study misses for Keytruda
BioPharma Dive
Merck
clinical trials
Keytruda
prostate cancer
lung cancer
Flag link:
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Fierce Biotech
cancer
Biocytogen
Chipscreen NewWay Biosciences
Merck
Keytruda
YH008
Flag link:
Warren urges US patent office to scrutinize Merck's efforts with Keytruda
Warren urges US patent office to scrutinize Merck's efforts with Keytruda
Fierce Pharma
Merck
Keytruda
Senate
Elizabeth Warren
patents
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow
Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow
Fierce Pharma
Merck
Keytruda
clinical trials
stomach cancer
Flag link:
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
Fierce Biotech
Merck
Keytruda
prostate cancer
Flag link:

Pages